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Introduction
Cancer progression and metastasis are dependent on changes in 
cancer cell adhesion and migration. To form metastases, cells 
that have detached from a primary tumor first invade the sur-
rounding tissues (Friedl and Alexander, 2011). Cells then enter 
the circulation either through the lymph or by migrating directly 
through blood vessel walls (intravasation), and disseminate 
throughout the body via the blood before adhering to endothe-
lial cells (ECs) lining the microvasculature (Madsen and Sahai, 
2010). Depending on the cancer origin and the target organ, 
tumor cells display different metastatic behaviors. They can ini-
tially proliferate in blood vessels and then extravasate (Al-Mehdi 
et al., 2000), or can directly extravasate as single cells and then 
invade into the tissues (Gassmann et al., 2009; Martin et al., 
2010). To form secondary tumors, they then need to survive and 
proliferate in this new environment (Joyce and Pollard, 2009; 
Nguyen et al., 2009). Both cell–cell adhesion molecules and 
chemokines, as well as their receptors, can contribute to metas-
tasis (Joyce and Pollard, 2009; Madsen and Sahai, 2010).
Rho family GTPases play a central role in cell migration 
and invasion by coordinately regulating cytoskeletal dynam-
ics and turnover of cell–cell and cell–ECM adhesions (Vega 
and Ridley, 2008; Ridley, 2011). They predominantly act on 
membranes and affect membrane dynamics by regulating actin 
polymerization. So far, 20 Rho family members have been 
identified in humans (Vega and Ridley, 2007). The expression 
level of several Rho GTPases is frequently altered in tumors 
and metastases, and this often correlates with poor prognosis 
(Kusama et al., 2006; Vega and Ridley, 2008). Several Rho 
GTPases or their targets have been specifically implicated in 
the metastatic process in animal models for cancer progression, 
including RhoC, Rho kinases, and PAKs, although the steps of 
metastasis that they regulate have not been defined precisely 
(Hall, 2009).
Here, we identify Cdc42 as a key regulator of cancer cell 
transendothelial migration (TEM) in a Rho GTPase RNAi 
Cancer cells interact with endothelial cells during the process of metastatic spreading. Here, we use a small interfering RNA screen targeting Rho 
GTPases in cancer cells to identify Cdc42 as a critical 
regulator of cancer cell–endothelial cell interactions and 
transendothelial migration. We find that Cdc42 regulates 
1 integrin expression at the transcriptional level via the 
transcription factor serum response factor (SRF). 1 inte-
grin is the main target for Cdc42-mediating interaction 
of cancer cells with endothelial cells and the underlying 
extracellular matrix, as exogenous 1 integrin expression 
was sufficient to rescue the Cdc42-silencing phenotype. 
We show that Cdc42 was required in vivo for cancer cell 
spreading and protrusion extension along blood vessels 
and retention in the lungs. Interestingly, transient Cdc42 
depletion was sufficient to decrease experimental lung 
metastases, which suggests that its role in endothelial 
attachment is important for metastasis. By identifying 1 
integrin as a transcriptional target of Cdc42, our results 
provide new insight into Cdc42 function.
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to characterize the function of Cdc42 during cancer cell TEM, 
comparing with Rac1 and RhoA as examples of Rho GTPases 
that have a similar effect to Cdc42 on adhesion to ECs but do 
not strongly alter intercalation.
Cdc42, Rac1, and RhoA have similar 
effects on EC junction opening
We next aimed to identify the steps of the TEM process spe-
cifically regulated by Cdc42. We first analyzed how Cdc42, 
Rac1, and RhoA affect endothelial junction opening. By 30 min 
after addition to ECs, most control PC3 cells had reached cell–
cell junctions and started to induce localized gaps between 
ECs directly underneath or near their site of adhesion, identi-
fied by the local disappearance of the adherens junction pro-
teins -catenin (Fig. 3 A) and VE-cadherin (not depicted). 
Cells first extend protrusions across the endothelial surface, 
toward EC junctions, which then induce localized gaps fol-
lowed by their progressive opening (Fig. S1 A). By 60 min, 
many had induced endothelial retraction and spread between 
ECs (Fig. 3 A). At these time points, Cdc42-, Rac1-, and 
RhoA-depleted cells were less frequently localized on top 
of an EC junction compared with control cells (Fig. 3, A and 
B), which suggests that they move more slowly to these sites. 
Indeed, time-lapse microscopy tracking showed they moved 
30% slower on ECs (not depicted). Moreover, when they 
were localized on top of a junction, fewer cells induced the 
local disappearance of junctional proteins or formation of inter-
cellular gaps (Fig. 3, A and C). Altogether these data show that 
Cdc42, Rac1, and RhoA depletion all delay EC junction open-
ing, which suggests that this is due to reduced initial adhesion, 
which they all affect similarly (Fig. 1). Cdc42-specific func-
tions required for intercalation therefore are likely to occur at a 
later stage of TEM.
Cdc42 regulates cancer cell interactions 
with the subendothelial ECM
After junctional opening, cancer cells interact with the ECM 
underlying the ECs in order to spread and intercalate be-
tween ECs (Reymond et al., 2012). We therefore investigated 
whether Cdc42 selectively affects this step of TEM. Analysis 
of movies showed that control cancer cells first extended mul-
tiple dynamic protrusions on top of the EC toward junctions, 
and subsequently on the ECM underlying a gap between ECs, 
then rapidly flattened out and spread by inducing retraction of 
neighboring ECs (Video 2). Intercalated cancer cells moved 
within the EC monolayer, eventually leading to gaps between 
ECs. In contrast, the Cdc42-depleted cells that did intercalate 
were taller than control, RhoA-depleted, or Rac1-depleted 
cells because they did not spread and their nuclei remained 
above the monolayer (Fig. 4 A and not depicted). Movies of 
Cdc42-depleted cells showed that they extended protrusions 
in all directions but did not spread or integrate into the EC 
monolayer efficiently (Fig. 4 B and Video 2). Rac1- and RhoA-
depleted cells did not show this behavior. This suggests that 
Cdc42 but not Rac1 or RhoA mediates cancer cell interactions 
with the subendothelial ECM. Indeed, Cdc42-depleted cells 
showed a similar behavior when attaching to ECM proteins: 
screen. We demonstrate that Cdc42 regulates 1 integrin at the 
transcriptional level via serum response factor (SRF), and that 
this is the major mechanism whereby Cdc42 regulates cancer 
cell TEM. We find that transient Cdc42 depletion is sufficient to 
decrease early cancer cell colonization in the lungs and to in-
hibit experimental metastasis formation in vivo. Our results in-
dicate that targeting the early steps of cancer cell interaction 
with ECs could inhibit metastasis.
Results
Effects of Rho GTPases on cancer cell 
adhesion to ECs
During TEM, cancer cells first adhere to ECs, open EC junc-
tions, induce endothelial retraction, and then insert into the 
endothelial monolayer between ECs, a process we name inter-
calation (Reymond et al., 2012). Of the cancer cell lines we 
tested (see Table S1), PC3 and DU145 prostate cancer cells 
and MDA-MB-231 breast cancer cells showed the highest 
level of adhesion and intercalation and thus were used in 
our experiments.
An siRNA screen was performed to determine which Rho 
GTPases affect cancer cell adhesion to ECs. PC3 cells were 
used for this screen because they express all 20 Rho GTPase 
genes, whereas DU145 and MDA-MB-231 cells do not (unpub-
lished data). siRNA pools targeting RhoA, RhoC, Rac1, Rac3, 
Cdc42, Rnd2, RhoH, and RhoBTB1 significantly reduced adhe-
sion by >25%, whereas RhoQ depletion increased adhesion by 
45% compared with control cells (Fig. 1 A). Two different sin-
gle siRNAs similarly reduced adhesion for Cdc42, Rac1, and 
RhoA (Fig. 1 B). Cdc42, Rac1, and RhoA depletion also reduced 
adhesion of DU145 cells to ECs (Fig. 1 C).
Cdc42 depletion strongly impairs 
intercalation
To investigate whether the reduced adhesion of Rho GTPase–
depleted cells to ECs affected subsequent PC3 cell intercala-
tion, we monitored cells by time-lapse microscopy (Fig. 2 A 
and Video 1). These experiments showed that Cdc42-depleted 
cancer cells had the strongest delay in intercalation of the ad-
hesion screen hits that we tested (Fig. 2 B, Video 1, and not 
depicted). Approximately 50% of Cdc42-depleted PC3 and 
DU145 cells had still not intercalated by 300 min (Fig. 2 B and 
Fig. S1 B). Similarly, Cdc42 depletion in MDA-MB-231 cells 
strongly inhibited intercalation (Fig. S1 C). Rac1- and RhoA-
depleted PC3 and DU145 cells showed a delay in intercalation, 
but by 300 min they had caught up with control cells (Fig. 2 B). 
Depletion of other tested Rho GTPases similarly delayed inter-
calation or had no effect (unpublished data). The effects of 
Cdc42, Rac1, and RhoA depletion on PC3 cell intercalation 
were rescued by expression of siRNA-resistant cDNAs (Fig. 2 C 
and Fig. S2). Cdc42-depleted cells crawled a longer distance on 
ECs, reflecting their reduced intercalation (Fig. 2 D; note that 
cells that did not intercalate were included). Cdc42 therefore 
regulates both cancer cell adhesion and intercalation, whereas 
other Rho GTPases contribute to cancer cell adhesion but do not 
have a long-term effect on intercalation. We therefore decided 
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Figure 1. Several Rho GTPases regulate cancer cell adhesion to ECs. (A and B) PC3 cells transfected with the indicated siRNA pools (A) or single siRNAs 
(B) were added to HUVECs for 15 min, and the percentage adhesion relative to control was determined. Data are expressed as the percentage of total 
cells analyzed. (C) DU145 cells transfected with siRNAs targeting Cdc42, Rac1, and RhoA or control siRNA (control) were added to confluent HUVECs 
for 30 min, and the number of cells adhering to ECs was scored. Data are presented as percentages with respect to control cells. (D) Lysates of PC3 cells 
transfected with indicated single siRNAs were immunoblotted as shown. Values (A–C) are means ± SEM (error bars; n ≥ 3); ***, P < 0.001; **, P < 0.01; 
*, P < 0.05. (E) Confocal images of PC3 cells transfected with single siRNAs as indicated. Cells were fixed and stained with DAPI (blue) and for F-actin 
(grayscale). Arrows indicate F-actin–rich protrusions (control, RhoA, Cdc42); arrowheads indicate an elongated tail (RhoA), cells with no F-actin-rich protru-
sions (Rac1), or an area of membrane retraction between F-actin–rich protrusions (Cdc42). Bar, 20 µm.
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Figure 2. Cdc42 depletion inhibits cancer cell intercalation between ECs. (A) CFSE-labeled PC3 cells transfected with control siRNA were filmed for 
300 min on HUVECs. Asterisks mark PC3 cells that intercalate; arrowheads indicate a cell that does not intercalate. Bar, 50 µm. (B and C) Graphs 
show time of intercalation for individual cells. Cells were filmed on HUVECs for 300 min. In each experiment, ≥100 cells were analyzed in at least 
three fields. Data are expressed as the percentage of total cells. (B) PC3 cells transfected with the indicated siRNAs. (C) PC3 cells transfected with the 
indicated siRNAs were transfected after 48 h with siRNA-resistant-cDNAs encoding GFP-tagged Cdc42, Rac1, and RhoA, respectively. (D) Distance 
migrated on top of ECs before intercalation. Data are expressed as the percentage of control cells. Values (B–D) are means ± SEM (error bars; n ≥ 3); 
***, P < 0.001; **, P < 0.01; *, P < 0.05.
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(Charras and Paluch, 2008). We observed that a proportion of 
Cdc42-depleted PC3 cells blebbed for long periods after adhe-
sion (Fig. 4 D, bottom), presumably reflecting their reduced 
adhesion so that they are “trapped” in an early stage of spread-
ing (Dubin-Thaler et al., 2008; Norman et al., 2010). These 
cells were not apoptotic because they eventually spread, and 
we did not observe any decrease in viability of Cdc42-depleted 
cells (unpublished data). Our observations together indicate 
they extended small protrusions in multiple directions and had 
defective spreading compared with control cells, which spread 
quite uniformly by extending lamellipodia around the peri-
phery (Fig. 4, C and D; and Video 3). Cdc42-depleted but not 
RhoA- or Rac1-depleted cells also showed reduced adhesion to 
fibronectin, Matrigel, or uncoated plastic (Fig. 4, E and F; and 
not depicted). In addition to lamellipodia, cells can generate 
highly dynamic plasma membrane protrusions known as blebs 
Figure 3. Cdc42, Rac1, and RhoA depletion inhibits EC junctional opening. (A) CFSE-labeled PC3 cells were added to HUVECs for 30 and 60 min, then 
stained for -catenin and F-actin. Cell outlines are shown. A gap in the endothelial monolayer by the control PC3 cell is outlined and marked with an 
asterisk. Arrows show the disappearance of -catenin. Bar, 50 µm. (B and C) Quantification of sites of cancer cell adhesion with respect to EC junctions 
and the status of EC junctions near cancer cell adhesion sites. Data are expressed as the percentage of total cells analyzed; ≥50 cells/experiment. Values 
are means ± SEM (error bars; n ≥ 3); ***, P < 0.001; **, P < 0.01; *, P < 0.05.
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Figure 4. Cdc42 depletion specifically reduces cancer cell adhesion and spreading to ECM. PC3 cells were transfected with the indicated siRNAs. 
(A) Confocal stack images of PC3 cells labeled with CFSE (green) and added to HUVECs for 4 h. Cells were stained with DAPI (blue) and for F-actin (red). 
Z views show cell height. Bar, 18 µm. (B) Time-lapse stills (Video 2) of PC3 cells on ECs. Bar, 50 µm. (C) Time-lapse stills (Video 3) of PC3 cells on fibronec-
tin. Bar, 50 µm. (D) Kymographs (right panels) from time-lapse movies of cells plated on fibronectin. First and last images of time-lapse movies are shown 
(left panels); arrows represent where the kymographs were made. Blebbing regions are indicated with white brackets (bottom right panel). Cell adhesion 
to fibronectin- (E) or Matrigel-coated (F) dishes at 15 min. Data (E and F) are expressed as the percentage of control cells. Values are means ± SEM (error 
bars; n ≥ 3); ***, P < 0.001; **, P < 0.01; *, P < 0.05.
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showing that we injected the same number of each cell popu-
lation, whereas at 6 h the ratio was 60:40, and at 24 h it was 
80:20 (Fig. 5 C). Our results strongly suggest that the defect in 
spreading of Cdc42-depleted cells to ECs leads to a decrease in 
early lung colonization.
Transient Cdc42 depletion reduces 
metastasis formation in vivo
The requirement for Cdc42 in initial cancer cell interaction 
with the lung endothelium could affect subsequent forma-
tion of metastases. To investigate this possibility, we injected 
Cdc42-depleted PC3 cells or control cells in the tail vein. 
By using transient Cdc42 depletion and injecting the cells 
3 d after siRNA transfection, we were able to specifically 
target Cdc42-regulated events happening during the first few 
days after the injection of the cells, as Cdc42 expression is 
knocked down very efficiently at 3 d after siRNA transfec-
tion and returns to normal levels between 6 and 10 d after 
transfection (Fig. S3 D).
Mice injected with Cdc42-depleted PC3 cells developed 
significantly less metastatic foci on the surface of lungs than 
control siRNA-transfected cells (Fig. 5, D and E). The foci 
were categorized based on size: for all the size categories we 
observed a decrease in the number of foci when Cdc42 had 
been depleted (not depicted). In addition, whereas almost all 
the mice injected with control cells developed metastatic foci 
on the rib cage, there were no foci on the rib cage in any mice 
injected with Cdc42-depleted cells (Fig. S3 E). To determine 
whether Cdc42 affected metastasis formation for another cell 
type, we injected mice with Cdc42-depleted MDA-MB-231 
cells. Although MDA-MB-231 cells formed few lung surface 
metastatic foci compared with PC3 cells, Cdc42 depletion led 
to a marked reduction in foci in sections through the lungs 
(Fig. 6, A and B). Interestingly, we observed that PC3 cells 
rarely formed foci inside the lungs; nearly all foci were near 
the surface (unpublished data). Because Cdc42 expression is 
only transiently reduced for a few days and does not seem to 
affect cell division in vitro, this strong inhibition of metastasis 
formation suggests that targeting the interaction of cancer 
cells with the endothelium through Cdc42 depletion is suffi-
cient to reduce experimental metastasis in vivo.
Cdc42 regulates 1 integrin levels  
and localization
To investigate the molecular basis for the defects of adhe-
sion and spreading on ECs and the subendothelial ECM ob-
served after Cdc42 depletion, we investigated whether Cdc42 
affected integrin levels. Integrins are a large family of het-
erodimeric cell adhesion molecules involved in the interac-
tions between cells and the ECM and between different cell 
types, for example, leukocytes and ECs (Humphries, 2000). 
Using flow cytometry, we confirmed that PC3 cells express 1, 
3, and 4 but not 2 integrins (not depicted), as reported 
previously (Liu, 2000). We observed a significant decrease 
in cell surface levels of 1 integrin in Cdc42-depleted cells 
compared with control cells, whereas surface levels of 2, 
3, and 4 integrins were not altered (Fig. 7 A and not depicted). 
that Cdc42-depleted cells have a strong defect in adhesion to 
ECM that inhibits intercalation.
To determine whether Cdc42 affected the whole TEM 
process, we used a 3D assay in which ECs were grown on a 
thick collagen I layer (Cain et al., 2011). Cdc42 depletion 
strongly inhibited extravasation of MDA-MB-231 cells: at 6 h, 
>50% of Cdc42-depleted cells remained rounded on top of 
ECs, whereas control cells had intercalated and started to 
invade the ECM underneath ECs (Fig. S1, D and E).
Cdc42 is required for the spreading  
and colonization of cancer cells in the  
lung vasculature in vivo
Because Cdc42 depletion reduced all the steps of TEM 
in vitro, we investigated whether Cdc42 affected the inter-
actions of cancer cells with vascular ECs in mouse lungs 
in vivo. YFP control and CFP-Cdc42–depleted PC3 cells 
were coinjected in the vena cava or in the tail vein 72 h after 
siRNA transfection to allow the behavior of Cdc42-depleted 
cells to be compared with control cells at the same time and 
in the same animal. EC lining blood vessels were stained by 
injecting a phycoerythrin (PE)-labeled anti–PECAM-1 anti-
body. At different time points after injection (10 min, 6 h, 
or 24 h), the lung–heart complex was isolated, inflated, and 
analyzed by confocal microscopy, as described previously 
(Im et al., 2004).
We observed that 90% of YFP-PC3 control cells already 
had one or multiple cell protrusions extending along the ves-
sels at 10 min after injection. This phenotype was maintained 
at 6 and 24 h. At these time-points, very few had extravasated 
(Fig. 5, A and B; and Video 4), which is consistent with pre-
vious observations using other cancer cell types (Al-Mehdi et al., 
2000). In contrast to control cells, most CFP-Cdc42–depleted 
cells did not extend protrusions and remained round or dis-
played a tubular vessel shape indicating that they had reduced 
interaction with the endothelium (Fig. 5, A and B; and Video 5). 
Similar results were obtained using CFP control cells and YFP-
PC3 Cdc42-depleted cells (Fig. S3, A and B). To study the inter-
action of cancer cells with ECs in more detail, we analyzed the 
localization of endothelial PECAM-1 around cancer cells in the 
lung blood vessels (Fig. S3 C). PECAM-1 staining was higher 
around Cdc42-depleted cells than control cells, which suggests 
that control cancer cells but not Cdc42-depleted cells had dis-
placed ECs and started to intercalate in vivo, or, alternatively, 
that control cells were more strongly attached to the endothe-
lium and thereby prevented access of PECAM-1 antibodies. 
Altogether, we show for the first time that Cdc42 is required 
for spreading of cancer cells in blood vessels in vivo.
In the lungs, cancer cell death is high during the first 24 h 
in the lung vasculature (up to 99% of injected cells; Mehlen 
and Puisieux, 2006). We therefore investigated whether Cdc42 
depletion affected early colonization of PC3 cells in the lungs. 
In vitro, Cdc42 depletion did not detectably affect cell pro-
liferation over 3 d (unpublished data). We quantified the ratio 
between YFP-PC3 control cells and CFP-Cdc42–depleted PC3 
cells during the first 24 h after injection in the tail vein or vena 
cava. At 10 min, the ratio of YFP cells/CFP cells was 50:50, 
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Figure 5. Cdc42 regulates PC3 cancer cell spreading on lung vascular ECs, retention in the lungs, and metastasis formation in vivo. CFP-PC3 cells trans-
fected with Cdc42 siRNA and YFP-PC3 cells transfected with control siRNA were coinjected into mice. (A) 3D reconstructions of representative confocal 3D 
stacks of cells in the lung vasculature. Arrows indicate cancer cell protrusions along the vessels. Bar, 20 µm. (B) Quantification of spread cells in the lung 
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glycosylated protein, and that the lower band is the cytosolic 
precursor; unpublished data; Isaji et al., 2009). Active 1 
integrin levels were similarly decreased in Cdc42-depleted 
cells, as determined by immunostaining with the 12G10 anti-
body (not depicted). Interestingly, the protein levels of 1 
integrin returned to normal levels 6 d after Cdc42 depletion, 
following a time course similar to Cdc42 levels (Fig. S3 D). 
1 integrin normally localized to actin-rich protrusions of 
A similar decrease in surface 1 integrin was sufficient to 
impair cell adhesion to ECM (Margadant et al., 2012). Rac1, 
RhoA, or RhoQ knockdown did not alter 1 integrin levels 
(unpublished data). The total level of 1 integrin was also 
decreased by Cdc42 depletion in PC3, DU145, and MDA-
MB-231 cells, as determined by immunoblotting and immuno-
fluorescence (Fig. 7, B and C; and Fig. S4, A–C; note that 
the upper 1 integrin band on blots is the mature cell surface 
vasculature. At least 50 single cells per condition were analyzed from at least three independent experiments. Data are expressed as the percentage of the 
total number of cells analyzed. (C) Number of cells in the lungs. 60 random independent fields were analyzed and the cell number was scored from three 
independent experiments. Data are expressed as the percentage of total cells analyzed. Values are means ± SEM (error bars); *, P < 0.05. (D) Effects of 
Cdc42 depletion on experimental metastasis formation. Mice were injected intravenously with PC3 cells transfected with control siRNA or Cdc42 siRNA. 
Quantification of metastatic foci on the lung surface (8 mice for control, 6 mice for Cdc42 siRNA). Values are means ± SEM (error bars); **, P < 0.01. 
(E) Representative images of lungs from mice injected with Cdc42-depleted cells (right) or control siRNA-transfected cells (left). Boxed regions are shown at 
higher magnification (bottom). Bars, 10 mm.
 
Figure 6. Transient Cdc42 depletion reduces 
MDA-MB-231 cell metastasis in vivo. SCID 
mice were injected in the tail vein with MDA-
MB-231 cells transfected with a control siRNA 
(Control) or with Cdc42-1 and Cdc42-2 
siRNAs. (A) Representative images of whole 
lung sections stained with hematoxylin and 
eosin. Bar, 20 mm. (B) Quantification of the 
percentage of lung areas positive for foci. 
Values are means ± SEM (error bars); *, P < 
0.05; ***, P < 0.001; determined by a two-
way ANOVA test.
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Figure 7. Cdc42 regulates 1 integrin expression levels. PC3 cells were transfected with the indicated siRNAs. (A) FACS analysis for 1 integrin. A 
representative FACS histogram (left) and quantification of FACS analyses (right) are shown; n ≥ 3. (B) Cell lysates were immunoblotted for Cdc42, 1 
integrin, and GAPDH expression. A representative blot is shown (left), as is a quantification of three independent blots for 1 integrin (right). (C) Repre-
sentative images of cells fixed and stained with DAPI (blue), for F-actin (red) and 1 integrin (green). Arrows indicate actin-rich protrusions. Boxed regions 
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are magnified in the “zoom” column. Bar, 50 µm. (D) Quantification of 1 integrin localization in F-actin–rich protrusions, n = 3. (E) FACS analysis 
for 1 integrin after Cdc42 depletion and reexpression of a Cdc42-siRNA–resistant-cDNA; n = 3. Values are means ± SEM (error bars); *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. See also Fig. S6.
 
PC3 cells, but in Cdc42-depleted cells, the remaining 1 integrin 
was rarely localized in protrusions (Fig. 7, C and D). The 
reduction in 1 integrin was rescued with siRNA-resistant 
cDNA encoding Cdc42 (Fig. 7 E and Fig. S4 D). In contrast 
to 1 integrin, Cdc42 did not affect levels of N-cadherin or 
CD44 (not depicted), which have previously been reported 
to regulate cancer cell interaction with ECs (Qi et al., 2005; 
Wang et al., 2005). Altogether, our results demonstrate that 
Cdc42 specifically regulates 1 integrin expression.
1 integrin is the main Cdc42 target 
required for cancer cell intercalation  
and TEM
Because Cdc42 regulates 1 integrin levels, we investigated 
the effect of 1 integrin depletion on cancer cell interaction 
with ECs. Two different siRNAs efficiently knocked down 1 
integrin expression in PC3 cells, as observed by flow cyto-
metry (Fig. 8 A), immunofluorescence, and immunoblotting 
(Fig. S5, A and B). 1 integrin depletion reduced PC3 cell 
adhesion to both ECs and fibronectin, and decreased TEM 
(Fig. 8, B–D). However, 1 integrin depletion had the strongest 
effect on intercalation, similar to Cdc42 depletion: >50% of 1 
integrin-depleted cells still did not intercalate between ECs after 
300 min (Fig. 8 E, Fig. S5 C, and Video 6). Most 1 integrin– 
depleted PC3 cells remained rounded and did not move on top 
of ECs (Fig. 8 E and Video 6), and we observed some cells bleb-
bing when trying to intercalate (unpublished data). 1 integrin 
depletion also had a similar phenotype to Cdc42 depletion during 
cell spreading on fibronectin: 1 integrin–depleted cells extended 
protrusions in multiple directions, and had reduced or delayed 
spreading (unpublished data). Importantly, exogenous 1 integrin 
expression (Fig. S5, D and E) rescued the reduced intercalation 
of Cdc42-depleted cancer cells, whereas exogenous 1 integrin 
alone did not increase intercalation (Fig. 8 F). This demonstrates 
that the decrease in 1 integrin expression induced by Cdc42 
depletion is sufficient to explain the defect in cancer cell interac-
tion with ECs and the ECM. 1 integrin regulation by Cdc42 is 
therefore crucial for cancer cell interaction with ECs.
Figure 8. 1 integrin regulates cancer cell interaction with ECs. PC3 cells were transfected with the indicated siRNAs. (A) 1 integrin levels were analyzed 
by FACS. (B–D) Shown is the number of adherent cells on HUVECs (B) or fibronectin-coated dishes (C) for 15 min (D) TEM of PC3 cells. (E and F) Time of 
intercalation for individual cells. Values (B–F) are means ± SEM expressed as the percentage of the total number of cells (n ≥ 3); *, P < 0.05; **, P < 0.01; 
***, P < 0.001; See also Fig. S7.
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had long-term effects on intercalation. The mechanistic basis of 
the involvement of the other Rho GTPases during cancer cell 
adhesion to ECs is currently being investigated; based on our 
results, at least for RhoA and Rac1, it is unlikely to involve 
changes to 1 integrin levels. Several Rho proteins are known 
to affect cancer cell invasion in vitro and in vivo (Vega and 
Ridley, 2008), but little is known of their roles in the specific 
step of extravasation. RhoA and RhoC depletion have been re-
ported to increase PC3 cell adhesion to a bone marrow EC cell 
line, whereas Rac1 and RhoC but not RhoA depletion reduced 
diapedesis measured in Transwells (Sequeira et al., 2008; van 
Golen et al., 2008). In contrast, we found that both RhoA and 
RhoC depletion in PC3 cells reduced adhesion to human umbil-
ical vein ECs (HUVECs). The reasons for these discrepancies 
are unknown but could be caused by the use of an EC line, 
whereas we used primary ECs.
Although Cdc42-, Rac1-, or RhoA-depleted cells all had 
lower adhesion to ECs, only depletion of Cdc42 decreases 1 
integrin expression, which then reduces intercalation as well as 
adhesion and spreading on the subendothelial ECM. 1 integrin 
has recently been described to regulate contractile forces that 
facilitate cancer cell invasion within the ECM (Mierke et al., 
2011). Thus, any protrusions from Cdc42-depleted cancer cells 
that do extend between ECs might not attach for long enough 
to the ECM to sustain EC junction opening. In addition, protru-
sions on Cdc42-depleted cells show a high level of membrane 
blebbing, and thus may not be able to provide the sustained me-
chanical force required to disrupt EC junctions.
We show that Cdc42 regulates 1 integrin expression. 
Consistent with our results, Cdc42 knockout hematopoietic 
stem cells were reported to have reduced 1 integrin expres-
sion levels (Yang et al., 2007), but the molecular basis for 
this decrease was not known. We found that Cdc42 regulates 
1 integrin transcription through the SRF transcription fac-
tor. Although SRF activity is most frequently associated with 
RhoA, Cdc42 has also been shown to stimulate SRF (Hill 
et al., 1995). In addition, Vav GEFs were found to induce SRF 
activation through Cdc42 and Rac1 (Charvet et al., 2002). 
Recently, 1 integrin expression was shown to be repressed 
by a novel protein SCA1, which binds to the SRF cofactor 
MAL (Brandt et al., 2009). SRF was reported to bind to the 
promoter of the 1 integrin gene (Brandt et al., 2009), and 
we found that SRF depletion dramatically reduced expression 
of a 1 integrin promoter in PC3 cells. Cdc42 could affect 
SRF/MAL activity through regulating G-actin levels (Olson 
and Nordheim, 2010), as its depletion strongly reduces F-actin 
levels. Interestingly, in our model, only Cdc42 but not RhoA 
affects 1 integrin levels, and RhoA was not required for Cdc42 
to activate SRF. Cdc42 might therefore activate another tran-
scription factor that acts together with SRF to stimulate 1 
integrin gene expression.
Lower 1 integrin levels are likely to contribute to the 
reduction in cancer cell spreading and protrusion extension 
that we observed in Cdc42-depleted cells in the lung vascu-
lature. Indeed, 1 integrin has been shown to be required for 
early entrapment of cancer cells in the lung (Wang et al., 2004) 
and to be involved in the metastasis process and formation of 
Cdc42 regulates 1 integrin at the 
transcriptional level via SRF activation
Because depletion of Cdc42 dramatically decreased 1 inte-
grin protein levels, we tested if it affected 1 integrin transcrip-
tion. 1 integrin mRNA levels were reduced by nearly 50% 
after Cdc42 depletion (Fig. 9 A). We used a 3,000-bp region 
upstream of the 1 integrin ATG to determine whether Cdc42 
affected 1 integrin gene expression. Cdc42 depletion reduced 
the activity of this 1 integrin promoter in PC3 cells (Fig. 9 B). 
Conversely, expression of wild-type Cdc42 or constitutively 
active Cdc42-V12 stimulated transcription from the 1 inte-
grin promoter (Fig. 9 C). The SRF/megakaryoblastic leukemia 
1 (MAL) transcription factor complex has been reported to 
regulate 1 integrin transcription (Brandt et al., 2009). Wild-
type and constitutively active Cdc42 stimulated the activity of 
the SRF target c-fos promoter (Fig. 9 D), and Cdc42 depletion 
reduced the activity of this promoter in PC3 cells (Fig. 9 F). 
RhoA is well known to stimulate SRF (Hill et al., 1995; 
Olson and Nordheim, 2010), but Cdc42 did not act via RhoA, 
as RhoA depletion did not affect Cdc42-induced activation of 
the 1 integrin promoter (Fig. 9 E). Finally, the depletion of 
SRF in Cdc42-V12–expressing cells reduced the activity of the 
1 integrin promoter, demonstrating that Cdc42 activates the 
1 integrin promoter via SRF (Fig. 9 G). Moreover, 1 integ-
rin protein levels were also decreased by SRF depletion in PC3 
cells (Fig. 9 H) and Cos7 cells (not depicted).
Expression of SRF-VP16, a constitutively active form 
of SRF (Hill et al., 1994), rescued the inhibition of PC3 cell inter-
calation induced by Cdc42 depletion (Fig. 9 I). SRF/MAL 
activity is known to be increased by stimuli that induce actin 
polymerization (Olson and Nordheim, 2010), and, interest-
ingly, we noted that Cdc42-depleted cancer cells consistently 
had lower levels of F-actin (Fig. 7 C and Fig. S4, A and D). 
Altogether, our results demonstrate that Cdc42 regulates 1 
integrin transcription by acting on the SRF signaling pathway, 
and that this mechanism accounts for the effects of Cdc42 on 
cancer cell intercalation.
Discussion
In this study, we have investigated the mechanisms underlying 
the interactions of cancer cells with ECs. We demonstrate that 
Cdc42 in cancer cells regulates cancer cell TEM by contributing 
to multiple steps of the extravasation process. Although several 
Rho GTPases, including Cdc42, contribute to cancer cell adhe-
sion to ECs, Cdc42 is unique in strongly affecting intercala-
tion of cancer cells into the EC monolayer, and in regulating 
cancer cell spreading on the subendothelial ECM. Interestingly, 
Cdc42 mediates cancer cell intercalation primarily by regulat-
ing 1 integrin expression. In vivo, Cdc42 is also required for 
cancer cells to spread on ECs and early colonization in the lung. 
Finally, we demonstrate that the initial transient depletion of 
Cdc42 is sufficient to inhibit experimental metastasis, indicat-
ing that the role of Cdc42 in cancer–EC interaction is important 
for the metastatic process.
In addition to Cdc42, several other Rho GTPase family 
members affected cancer cell adhesion to ECs, but only Cdc42 
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of micrometastases in the lung (Shibue and Weinberg, 2009). 
Recent evidence shows that interfering with cancer cell attach-
ment and spreading by inhibiting 1 integrin sensitizes tumor 
cells to TRAIL-induced apoptosis (Phipps et al., 2011). It is 
thus possible that Cdc42 depletion similarly decreases resis-
tance to apoptotic signals induced by immune cells present in 
severe combined immunodeficiency (SCID) mice such as natu-
ral killer cells, which contribute to antitumoral protection in the 
lungs (Yang et al., 2006).
Cdc42 is well known to regulate cancer cell invasion 
in vitro and is overexpressed in several human tumor types 
metastatic foci in the lungs in vivo (Wang et al., 2004; Kren 
et al., 2007; Huck et al., 2010). Interestingly, 31 integrin is 
required for attachment of HT1080 fibrosarcoma cells to lam-
inin exposed in small gaps between ECs in the lung vasculature 
in vivo (Wang et al., 2004); in a zebrafish model, 1 inte-
grin mediates adhesion of cancer cells to the blood vessel wall 
(Stoletov et al., 2010).
The reduced levels of 1 integrin could also explain the 
lower retention of Cdc42-depleted cells in the lung, as 1 inte-
grin provides pro-survival and antiapoptotic signals. Indeed, the 
1 integrin–FAK signaling axis controls the initial proliferation 
Figure 9. Cdc42 regulates 1 integrin transcription via SRF. (A) 1 integrin mRNA levels quantified by quantitative PCR. (B–G) Activities of p3000 1 
integrin and c-fos promoters were assessed by luciferase assays after PC3 cell transfection with the indicated siRNAs (B), Cos7 cell transfection with wild-
type or constitutively active Cdc42-V12 (C and D), Cos7 cell transfection with Cdc42-V12 and RhoA siRNAs (E), PC3 cell transfection with the indicated 
siRNAs (F), and Cos7 cell transfection with SRF siRNAs (G). (H) Lysates of PC3 cells transfected as indicated were immunoblotted for SRF, 1 integrin, and 
GAPDH (loading control). A representative blot is shown (left) as well as a quantification of three independent blots for 1 integrin (right). (I) Time of inter-
calation for individual cells, expressed as the percentage of the total cell number. PC3 cells were transfected with SRF-VP16 24 h after siRNA transfection. 
Values are means ± SEM (error bars; n = 3); ***, P < 0.001; **, P < 0.01; *, P < 0.05.
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(Sigma-Aldrich) and used for functional assays as described previously. 
For Western blotting, cells were lysed by scraping into sample buffer 
(NuPAGE 4× SDS sample buffer; Invitrogen), then proteins were separated 
using precast NuPAGE 4–12% Bis-Tris gels (Invitrogen), transferred to 
nitrocellulose membrane (Immobilon), and incubated with antibodies in 
Tris-buffered saline containing 5% nonfat milk and 0.1% Tween-20.
Immunofluorescence
HUVECs were grown to confluency on 13-mm-diameter glass coverslips. 
CFSE-labeled PC3 cells (2.5 × 104) were added and were fixed at different 
time points with 3.7% paraformaldehyde in PBS for 20 min. Cells were 
permeabilized with 0.1% Triton X-100 for 5 min at 4°C and then blocked 
with 5% FCS in PBS for 20 min. Samples were incubated with primary 
antibodies for 60 min and then appropriate secondary antibodies (Molecular 
Probes) or dyes. Samples were mounted onto slides with mounting medium 
(Dako), and images acquired using a confocal microscope (510 LSM; Carl 
Zeiss) with a 40× objective lens and Zen software (Carl Zeiss). Images 
were processed using Photoshop software (Adobe).
Flow cytometry
PC3 cells were transfected with the appropriate siRNAs. After 72 h, 2 × 
105 cells were resuspended and incubated with the indicated antibodies 
and then with Alexa Fluor 488–labeled goat anti–mouse antibody. Sam-
ples were analyzed using a flow cytometer (FACSCalibur) and Cell Quest 
Pro (Software; both from BD) and processed using Flow Jo software.
Luciferase assay
Luciferase assays were performed as specified by the manufacturer (Pro-
mega). In brief, PC3 cells were transfected with siRNAs targeting Cdc42 
or with control siRNA, and after 48 h were transfected with the different re-
porter genes. Cos7 cells were transfected with different cDNAs (control, 
Cdc42, Cdc42-V12, SRF-VP16), and for siRNA experiments were also 
transfected again 24 h later with single siRNAs targeting SRF or control 
siRNA, then transfected again with the different reporter genes. PC3 cells 
and Cos7 cells were maintained in growth medium containing 10% FCS, 
and luciferase assays were performed 24 h after reporter gene transfec-
tion. c-fos and 1 integrin (containing the 3,000 bp upstream of the ATG 
start codon) reporter genes were provided by D. Brandt and R. Grosse 
(University of Marburg, Marburg, Germany).
Adhesion assay
CFSE-labeled PC3 cells (2 × 104) were added to confluent HUVECs in 96-
well plates for 15 min at 37°C, then washed once with PBS containing cal-
cium and magnesium. Each condition was performed at least in triplicate. 
Adherent cells were quantified with a Fusion -FP plate reader (PerkinElmer). 
Fusion 4.02 software and Microsoft Excel were used to acquire raw data 
and process them, respectively. Adhesion to fibronectin (10 µg/ml; Sigma-
Aldrich)- and Matrigel (100 µg/ml; BD)-coated or uncoated plastic was 
quantified similarly.
TEM assay
HUVECs (5 × 104/well) were plated onto 10 µg/ml fibronectin-coated Co-
star Transwells (8-µm pore size and 6.5-mm diameter). After 24 h, 2.5 × 
104 CFSE-labeled PC3 cells were added. 40 ng/ml HGF was added as a 
chemo-attractant in the lower chamber. After 8 h at 37°C, PC3 cells were 
recovered from the bottom of the filter, resuspended in PBS containing 5% 
FCS, and counted by flow cytometry (FACSCalibur 3.7; BD). Results were 
processed using Cell Quest software. The 3D TEM assay, using HUVECs 
plated on a layer of Collagen-I, was carried out as described previously 
(Cain et al., 2011).
Time-lapse microscopy
CFSE-labeled PC3 cells (3 × 104) were added to confluent HUVECs on 24-
well plates. Cells were monitored by time-lapse microscopy for up to 5 h in 
a humidified chamber at 37°C and 5% CO2 with an inverted microscope 
(TE2000; Nikon) equipped with a motorized stage (Prior Scientific), with a 
10× or a 20× objective lens and using MetaMorph software (Molecular 
Devices). Cells were tracked manually using ImageJ software. To quantify 
intercalation, a cell was considered as intercalated when its shape was not 
round, when it was no longer phase-bright, and when it was clearly part of 
the EC monolayer.
To determine spread area, cells plated on 10 µg/ml fibronectin 
were imaged by time-lapse microscopy for 1 h, and the spread area of 
>100 cells acquired in each of three independent experiments was mea-
sured using ImageJ software.
(Vega and Ridley, 2008; Stengel and Zheng, 2011), but so far its 
effects on tumor growth and metastasis in vivo can be ex-
plained by changes in cell proliferation (Bouzahzah et al., 2001; 
Hua et al., 2011). It is therefore particularly interesting that, 
in our studies, transient depletion of Cdc42 at a critical step of 
the metastatic cascade was sufficient to reduce metastatic foci 
after 6 wk. In vitro, Cdc42 depletion in PC3 cells did not 
affect proliferation or cell division (unpublished data). It is 
possible that Cdc42-depleted cancer cells initially grow slower 
than control cells in vivo because of reduced 1 integrin sig-
naling. However, because we injected PC3 cells 3 d after their 
transfection with siRNA to Cdc42, and the levels of Cdc42 
and 1 integrin expression are close to normal 6 d after trans-
fection, our data clearly indicate that Cdc42-induced reduc-
tion of cancer cell interaction with ECs in the first 24 h after 
entry into blood vessels decreases the efficiency of metasta-
sis. Targeting Cdc42 would potentially affect cancer cell–EC 
interactions for multiple tumor types, whereas targeting cell 
adhesion molecules on the surface of cancer cells or ECs is 
more tumor type–specific (Madsen and Sahai, 2010). Inter-
estingly, we have observed in vitro that depletion of Cdc42 
in adherent PC3 cells induced their de-adhesion (unpublished 
data). Delivering Cdc42 inhibitors directly in the blood could 
therefore block the interaction of cancer cells to vessel walls, 
or help to detach already attached cancer cells, and hence re-
duce metastasis. Importantly, Cdc42 is not required for T cell 
TEM (Heasman et al., 2010) and thus is a potentially selective 
target to inhibit cancer cell metastasis without affecting leu-
kocyte trafficking.
Materials and methods
Cell culture and reagents
Primary HUVECs were maintained in EBM2 medium (Lonza) on dishes 
coated with 10 µg/ml fibronectin (Sigma-Aldrich). PC3 and DU145 were 
cultivated in RPMI-1640 medium supplemented with 10% FCS, 2 mM glu-
tamine, 100 U/ml penicillin, and 50 µg/ml streptomycin. MDA-MB-231 
and Cos7 cells were cultivated in DMEM medium supplemented with 10% 
FCS, 2 mM glutamine, 100 U/ml penicillin, and 50 µg/ml streptomycin. 
Stable CFP- and YFP-expressing PC3 cells were generated by transfection 
either with CFP or YFP in CB6 plasmids, respectively, using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions. An XTT 
assay was used to determine cell number and cell viability (Roche).
The following antibodies were used: RhoA (clone 26C4; Santa Cruz 
Biotechnology, Inc.), Rac1 (EMD Millipore), Cdc42 (clone B-8; Santa Cruz 
Biotechnology, Inc.), VE-cadherin (clone 75; BD), PECAM-1 (clone JC70A; 
Dako), PE-conjugated PECAM-1 (clone 390; BioLegend), -catenin (Sigma-
Aldrich), 1 integrin 4B7 (Abcam), 1 integrin 18/CD29 (BD), 1 integrin 
P4G11 (EMD Millipore), 1 integrin 12G10 (Abcam), 2 integrin P4H9 
(EMD Millipore), 3 integrin 25E11 (EMD Millipore), 4 integrin ASC-9 
(EMD Millipore), N-cadherin (Abcam), CD44 E4 (provided by I. Drans-
field, University of Edinburgh, Edinburgh, UK), Nectin-2 477 (provided 
by M. Lopez, Marseille, France), SRF (clone G-20; Santa Cruz Biotechnol-
ogy, Inc.), and GAPDH (EMD Millipore). HRP-conjugated antibodies (GE 
Healthcare) were detected with chemiluminescence reagent (Thermo Fisher 
Scientific). Cells were labeled with 2 µM 5-(and-6)-carboxyfluorescein 
diacetate succinimidyl ester (CFSE; Molecular Probes). Alexa Fluor 546– or 
TRITC-labeled phalloidin (1:400; Invitrogen) were used to detect F-actin.
Cell transfection and Western blotting
All siRNAs (Thermo Fisher Scientific) are single oligos (Table S1). PC3 cells 
(1.25 × 105) were plated and transfected after 24 h with individual oligos 
(100 nM) with Optimem-I and Oligofectamine (Invitrogen). After 72 h, cells 
were detached from culture plates with nonenzymatic cell dissociation solution 
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Visualization of cancer cell attachment in lung blood vessels
We used an established technique to observe and image fluorescently la-
beled tumor cells and capillary ECs in situ in isolated, ventilated blood-free 
lungs of SCID mice (6–8-wk-old females) by confocal microscopy, as previ-
ously described (Im et al., 2004). YFP-PC3 cells were transfected with a 
control siRNA, and CFP-PC3 cells were transfected with a Cdc42-specific 
siRNA, or vice versa. 72 h after transfection, both populations were 
injected in the vena cava (10-min time point) or in the tail vein (6 h and 24 h 
time points) of mice. Blood vessels were stained with a PE-conjugated 
mouse anti–PECAM-1 antibody injected in the vena cava 5 min before the 
animals were sacrificed. Images of PC3 cells and vascular lung ECs were 
acquired using a confocal microscope (LSM710; Carl Zeiss) at 405 nm 
(CFP), 488 nm (YFP), and 543 nm (TRITC) with a 20× (quantification ex-
periments) or a 40× (morphology experiments) objective lens. The morpho-
logical analysis was performed only on single cells or groups of two cells. 
2D and 3D images were processed using Photoshop (Adobe), Amira 
(VSG), and Volocity (PerkinElmer) software.
A custom algorithm was used to analyze the intensity of the 
endothelial PECAM-1 staining surrounding cancer cells. First, the cell 
image was thresholded (with a user-selected threshold). The image was 
then median filtered using a circle of radius 3, and any “holes” in the 
cell (dark areas that were completely surrounded by white areas) were 
filled. To find the pixels surrounding the cell, this image was then dilated 
(again using a circle of radius 3), and the pixels that were white in the 
dilated image but not the filled image were selected. To find the pixels 
inside the cell, the filled image was eroded with a circle with a radius 
of 1.9. The ratio of the mean value of those pixels in the vessel image 
corresponding to the surrounding image and corresponding to the inside 
of the cell was calculated.
Lung metastasis assay
PC3 or MDA-MB-231 cells were transfected with siRNAs. After 72 h, cells 
were detached from culture plates by incubation in a mild resuspension 
buffer (Sigma-Aldrich), and 106 cells exhibiting 90% viability were sus-
pended in 200 µl of serum-free RPMI before injection into the tail veins 
of SCID mice (6–8-wk-old female mice). After 4 (MDA-MB-231) or 6 wk 
(PC3), lungs were fixed and analyzed for the presence of surface meta-
static foci. Lung sections were then hematoxylin and eosin stained and 
scanned (Aperio scanner), and the tumor-covered areas were quantified 
with the Aperio software.
Statistical analysis
Each condition was performed in triplicate, and experiments were all per-
formed at least three times. Data are expressed as means ± SEM. Statistical 
significance of in vitro assays was determined by an unpaired Student’s t 
test. For 3D ex vivo analysis, at least 50 cells per condition were analyzed 
with at least three animals per condition. Statistical significance of in vivo 
assays was determined by a two-way ANOVA test. In all analyses, differ-
ences were considered statistically significant at P < 0.05.
Online supplemental material
Fig. S1 shows that Cdc42 regulates cancer cell–EC intercalation and trans-
migration in DU145 and MDA-MB-231 cells. Fig. S2 shows that Cdc42-, 
Rac1-, and RhoA-siRNA resistant cDNA transfection rescues morphological 
depletion phenotypes. Fig. S3 shows that Cdc42 depletion reduces cancer 
cell spreading on lung blood vessels in vivo and experimental metastasis. 
Fig. S4 shows that Cdc42 but not Rac1 or RhoA regulates 1 integrin cell 
surface levels. Fig. S5 shows 1 integrin depletion in PC3 cells. Table S1 
lists cancer cell lines tested for adhesion to and intercalation between 
ECs. Table S2 lists siRNA oligos used in experiments. Video 1 shows that 
Cdc42, Rac1, or RhoA depletion delays cancer cell intercalation. Video 2 
shows that Cdc42 depletion reduces cancer cell adhesion to ECs. Video 3 
shows that Cdc42 regulates cancer cell adhesion and spreading to fibro-
nectin. Video 4 shows that PC3 cells spread on vascular lung ECs in vivo. 
Video 5 shows that Cdc42 controls cancer cell spreading on vascular lung 
ECs in vivo. Video 6 shows that 1 integrin regulates cancer cell inter-
action with ECs. Online supplemental material is available at http://www 
.jcb.org/cgi/content/full/jcb.201205169/DC1.
We thank D. Brandt and R. Grosse for luciferase assay constructs, P. Bhavsar 
for analysis of Rho GTPase expression in PC3 cells, D. Soong for microscopy 
assistance, and F. Calhabeu, A. Ivetic, M. Parsons, P. Morton, V. Sanz-Moreno, 
and members of A.J. Ridley’s laboratory for helpful discussions.
This work was supported by Cancer Research UK, the Biotechnology 
and Biological Sciences Research Council, Breast Cancer Campaign, King’s 
JCB • VOLUME 199 • NUMBER 4 • 2012 668
Vega, F.M., and A.J. Ridley. 2008. Rho GTPases in cancer cell biology. FEBS 
Lett. 582:2093–2101. http://dx.doi.org/10.1016/j.febslet.2008.04.039
Wang, H., W. Fu, J.H. Im, Z. Zhou, S.A. Santoro, V. Iyer, C.M. DiPersio, 
Q.C. Yu, V. Quaranta, A. Al-Mehdi, and R.J. Muschel. 2004. Tumor 
cell 31 integrin and vascular laminin-5 mediate pulmonary arrest 
and metastasis. J. Cell Biol. 164:935–941. http://dx.doi.org/10.1083/ 
jcb.200309112
Wang, H.S., Y. Hung, C.H. Su, S.T. Peng, Y.J. Guo, M.C. Lai, C.Y. Liu, and 
J.W. Hsu. 2005. CD44 cross-linking induces integrin-mediated adhesion 
and transendothelial migration in breast cancer cell line by up-regula-
tion of LFA-1 ( L 2) and VLA-4 (41). Exp. Cell Res. 304:116–126. 
http://dx.doi.org/10.1016/j.yexcr.2004.10.015
Yang, Q., S.R. Goding, M.E. Hokland, and P.H. Basse. 2006. Antitumor ac-
tivity of NK cells. Immunol. Res. 36:13–25. http://dx.doi.org/10.1385/ 
IR:36:1:13
Yang, L., L. Wang, H. Geiger, J.A. Cancelas, J. Mo, and Y. Zheng. 2007. Rho 
GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche 
interaction in the bone marrow. Proc. Natl. Acad. Sci. USA. 104:5091–
5096. http://dx.doi.org/10.1073/pnas.0610819104
function: identification of the minimal N-glycosylation requirement for 
51. J. Biol. Chem. 284:12207–12216. http://dx.doi.org/10.1074/jbc 
.M807920200
Joyce, J.A., and J.W. Pollard. 2009. Microenvironmental regulation of metasta-
sis. Nat. Rev. Cancer. 9:239–252. http://dx.doi.org/10.1038/nrc2618
Kren, A., V. Baeriswyl, F. Lehembre, C. Wunderlin, K. Strittmatter, H. 
Antoniadis, R. Fässler, U. Cavallaro, and G. Christofori. 2007. Increased 
tumor cell dissemination and cellular senescence in the absence of 
1-integrin function. EMBO J. 26:2832–2842. http://dx.doi.org/10 
.1038/sj.emboj.7601738
Kusama, T., M. Mukai, M. Tatsuta, H. Nakamura, and M. Inoue. 2006. 
Inhibition of transendothelial migration and invasion of human breast 
cancer cells by preventing geranylgeranylation of Rho. Int. J. Oncol. 
29:217–223.
Liu, A.Y. 2000. Differential expression of cell surface molecules in prostate 
cancer cells. Cancer Res. 60:3429–3434.
Madsen, C.D., and E. Sahai. 2010. Cancer dissemination—lessons from 
leukocytes. Dev. Cell. 19:13–26. http://dx.doi.org/10.1016/j.devcel 
.2010.06.013
Margadant, C., M. Kreft, D.J. de Groot, J.C. Norman, and A. Sonnenberg. 
2012. Distinct Roles of Talin and Kindlin in Regulating Integrin 51 
Function and Trafficking. Curr. Biol. 22:1554–1563. http://dx.doi.org/ 
10.1016/j.cub.2012.06.060
Martin, M.D., G.J. Kremers, K.W. Short, J.V. Rocheleau, L. Xu, D.W. Piston, 
L.M. Matrisian, and D.L. Gorden. 2010. Rapid extravasation and estab-
lishment of breast cancer micrometastases in the liver microenvironment. 
Mol. Cancer Res. 8:1319–1327. http://dx.doi.org/10.1158/1541-7786 
.MCR-09-0551
Mehlen, P., and A. Puisieux. 2006. Metastasis: a question of life or death. Nat. 
Rev. Cancer. 6:449–458. http://dx.doi.org/10.1038/nrc1886
Mierke, C.T., B. Frey, M. Fellner, M. Herrmann, and B. Fabry. 2011. Integrin 
51 facilitates cancer cell invasion through enhanced contractile 
forces. J. Cell Sci. 124:369–383. http://dx.doi.org/10.1242/jcs.071985
Nguyen, D.X., P.D. Bos, and J. Massagué. 2009. Metastasis: from dissemina-
tion to organ-specific colonization. Nat. Rev. Cancer. 9:274–284. http://
dx.doi.org/10.1038/nrc2622
Norman, L.L., J. Brugués, K. Sengupta, P. Sens, and H. Aranda-Espinoza. 
2010. Cell blebbing and membrane area homeostasis in spreading and 
retracting cells. Biophys. J. 99:1726–1733. http://dx.doi.org/10.1016/ 
j.bpj.2010.07.031
Olson, E.N., and A. Nordheim. 2010. Linking actin dynamics and gene tran-
scription to drive cellular motile functions. Nat. Rev. Mol. Cell Biol. 
11:353–365. http://dx.doi.org/10.1038/nrm2890
Phipps, L.E., S. Hino, and R.J. Muschel. 2011. Targeting cell spreading: a 
method of sensitizing metastatic tumor cells to TRAIL-induced apopto-
sis. Mol. Cancer Res. 9:249–258. http://dx.doi.org/10.1158/1541-7786.
MCR-11-0021
Qi, J., N. Chen, J. Wang, and C.H. Siu. 2005. Transendothelial migration of 
melanoma cells involves N-cadherin-mediated adhesion and activation 
of the beta-catenin signaling pathway. Mol. Biol. Cell. 16:4386–4397. 
http://dx.doi.org/10.1091/mbc.E05-03-0186
Reymond, N., P. Riou, and A.J. Ridley. 2012. Rho GTPases and cancer cell tran-
sendothelial migration. Methods Mol. Biol. 827:123–142. http://dx.doi 
.org/10.1007/978-1-61779-442-1_9
Ridley, A.J. 2011. Life at the leading edge. Cell. 145:1012–1022. http://dx.doi 
.org/10.1016/j.cell.2011.06.010
Sequeira, L., C.W. Dubyk, T.A. Riesenberger, C.R. Cooper, and K.L. van Golen. 
2008. Rho GTPases in PC-3 prostate cancer cell morphology, invasion 
and tumor cell diapedesis. Clin. Exp. Metastasis. 25:569–579. http://
dx.doi.org/10.1007/s10585-008-9173-3
Shibue, T., and R.A. Weinberg. 2009. Integrin beta1-focal adhesion kinase sig-
naling directs the proliferation of metastatic cancer cells disseminated in 
the lungs. Proc. Natl. Acad. Sci. USA. 106:10290–10295. http://dx.doi 
.org/10.1073/pnas.0904227106
Stengel, K., and Y. Zheng. 2011. Cdc42 in oncogenic transformation, inva-
sion, and tumorigenesis. Cell. Signal. 23:1415–1423. http://dx.doi.org/ 
10.1016/j.cellsig.2011.04.001
Stoletov, K., H. Kato, E. Zardouzian, J. Kelber, J. Yang, S. Shattil, and R. 
Klemke. 2010. Visualizing extravasation dynamics of metastatic tumor 
cells. J. Cell Sci. 123:2332–2341. http://dx.doi.org/10.1242/jcs.069443
van Golen, K.L., C. Ying, L. Sequeira, C.W. Dubyk, T. Reisenberger, A.M. 
Chinnaiyan, K.J. Pienta, and R.D. Loberg. 2008. CCL2 induces pros-
tate cancer transendothelial cell migration via activation of the small 
GTPase Rac. J. Cell. Biochem. 104:1587–1597. http://dx.doi.org/10 
.1002/jcb.21652
Vega, F.M., and A.J. Ridley. 2007. SnapShot: Rho family GTPases. Cell. 
129:1430.e1–1430.e2. http://dx.doi.org/10.1016/j.cell.2007.06.021
